Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. plans to offer $500 million in convertible senior notes due 2032 and $200 million in common stock, subject to market conditions [1] Group 1: Financial Offerings - The company intends to issue $500 million aggregate principal amount of convertible senior notes due 2032 [1] - Additionally, Arrowhead plans to offer $200 million of common stock in separate public offerings [1] - The underwriters of the note offering will have a 30-day option to purchase up to an additional $75 million [1]